Sugi Predict

Sugi Predict / Compounds / SCHEMBL3670935

SCHEMBL3670935

SCHEMBL3670935

COc1cc(B2OC(C)(C)C(C)(C)O2)cc(C)n1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SNCA P37840 1/20 0.39
▸ LPL P06858 6/20 0.37
▸ LIPG Q9Y5X9 6/20 0.37
▸ IRAK4 Q9NWZ3 1/20 0.36
▸ CSF1R P07333 1/20 0.35
▸ PDE2A O00408 1/20 0.35
▸ CYP1A2 P05177 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA9 Q16790 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ DGAT1 O75907 1/20 0.34
▸ ALPL P05186 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ FFAR1 O14842 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29383901 1.00 SNCA (0.39) SNCALPLLIPGIRAK4CSF1R
SCHEMBL17667880 0.89 LPL (0.44) SNCALPLLIPGCSF1RPDE2A
SCHEMBL4671691 0.85 LPL (0.43) SNCALPLLIPGIRAK4CA1
SCHEMBL22324125 0.81 LPL (0.41) SNCALPLLIPGIRAK4CSF1R
SCHEMBL38657929 0.81 SNCA (0.39) SNCALPLLIPGCSF1RPDE2A
SCHEMBL3027012 0.81 SNCA (0.39) SNCALPLLIPGCSF1RPDE2A
SCHEMBL17667853 0.81 LPL (0.38) SNCALPLLIPGIRAK4CA1
SCHEMBL24227876 0.79 FFAR1 (0.35) SNCALPLLIPGIRAK4TDP1
SCHEMBL29384079 0.79 FFAR1 (0.35) SNCALPLLIPGIRAK4TDP1
SCHEMBL2725503 0.78 HSD17B10 (0.39) SNCALPLLIPGCSF1RKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4620533-A2 ANTAGONIST COMPOUNDS Adorx therapeutics Limited (GB) 2025-09-24 — — EP disclosed
EP-4188924-B1 ANTAGONIST COMPOUNDS ADORX THERAPEUTICS LTD (GB) 2025-06-18 — — EP disclosed
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-20250034153-A1 TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS INCYTE CORPORATION 2025-01-30 — — US disclosed
US-20230322675-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LHOTSE BIO, INC. 2023-10-12 — — US disclosed
US-20230293517-A1 ANTAGONIST COMPOUNDS JANSSEN PHARMCEUTICA NV (BE) 2023-09-21 — — US disclosed
US-20230271964-A1 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER NXERA PHARMA UK LIMITED (GB) 2023-08-31 — — US disclosed
US-20230271964-A1 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER NXERA PHARMA UK LIMITED (GB) 2023-08-31 — — US disclosed
CN-116648451-A Antagonist compounds 阿道尔克斯治疗有限公司 2023-08-25 — — CN disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
US-8969386-B2 Modulators of CFTR VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-03-03 — — US disclosed
US-8969386-B2 Modulators of CFTR VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-03-03 — — US disclosed
US-20150031708-A1 MODULATORS OF CFTR VERTEX PHARMACEUTICALS INCORPORATED 2015-01-29 — — US disclosed
US-20150031708-A1 MODULATORS OF CFTR VERTEX PHARMACEUTICALS INCORPORATED 2015-01-29 — — US disclosed
US-20150031708-A1 MODULATORS OF CFTR VERTEX PHARMACEUTICALS INCORPORATED 2015-01-29 — — US disclosed
EP-2789606-A1 Modulators of CFTR Vertex Pharmaceuticals Incorporated (US) 2014-10-15 — — EP disclosed
EP-2789606-A1 Modulators of CFTR Vertex Pharmaceuticals Incorporated (US) 2014-10-15 — — EP disclosed
EP-2164840-A2 MODULATORS OF CFTR Vertex Pharmaceuticals Incorporated (US) 2010-03-24 — — EP disclosed
WO-2008141119-A2 MODULATORS OF CFTR VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-20 — — WO disclosed
WO-2008141119-A2 MODULATORS OF CFTR VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322675-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LPAR2, LPAR1, LPAR6 SNCA 2824/4885LPL 11/4885LIPG 22/4885
US-20230293517-A1 ANTAGONIST COMPOUNDS ADORA2B, ADORA2A, ADORA1 SNCA 1693/4885LPL 4229/4885LIPG 3665/4885
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN SNCA 1168/4885LPL 3972/4885LIPG 3859/4885
US-20230271964-A1 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER ADORA2A, ADORA1, ADORA3 SNCA 1400/4885LPL 3804/4885LIPG 4196/4885
US-20150031708-A1 MODULATORS OF CFTR CFTR, ABCB1, ABCC4 SNCA 4484/4885LPL 870/4885LIPG 2491/4885
US-20250034153-A1 TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS ADORA2A, ADORA2B, ADORA1 SNCA 888/4885LPL 3435/4885LIPG 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.